氯胺酮与艾司氯胺酮抗抑郁治疗的安全性与精准给药:药物基因组学与药物相互作用视角
本文综述了CYP多态性及常见药物相互作用对氯胺酮和艾司氯胺酮药代动力学的影响,探讨其在长期抗抑郁使用中的剂量优化意义。氯胺酮与艾司氯胺酮经CYP2B6、CYP3A4、CYP2C9和CYP2A6等多态性酶代谢,抗抑郁治疗常联用多种CYP底物药物,增加相互作用风险。了解这些因素有助于优化剂量并识别不良反应高风险个体。
要点
- 氯胺酮和艾司氯胺酮经CYP2B6、CYP3A4、CYP2C9、CYP2A6等多态性酶代谢。
- 抗抑郁治疗常联用多种CYP底物药物,增加药物相互作用风险。
- 药物基因组学与相互作用信息可辅助剂量优化和识别不良反应高风险个体。
核心结论
- 氯胺酮和艾司氯胺酮的抗抑郁应用需更好理解影响其代谢与长期疗效的因素。
- 药物基因组学和药代动力学决定因素信息可辅助剂量优化和识别不良反应风险个体。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 氯胺酮和艾司氯胺酮经多态性CYP酶CYP2B6、CYP3A4、CYP2C9和CYP2A6代谢。
- 抗抑郁药物治疗通常联用多种CYP酶底物药物,增加药物相互作用风险。
- 氯胺酮和艾司氯胺酮的长期用药经验较少,其使用受神经毒性、拟精神病性副作用、滥用潜力和治疗反应个体间变异等限制。
临床怎么用
- 临床使用氯胺酮或鼻用艾司氯胺酮抗抑郁时,应关注CYP多态性和合并用药对代谢与疗效的潜在影响。
- 可结合药效学和药代动力学决定因素信息,辅助剂量优化和识别不良反应高风险个体。
局限性
- 氯胺酮和艾司氯胺酮作为长期抗抑郁药物的经验较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ketamine and its enantiomer S-ketamine (esketamine) are known to produce rapid-onset antidepressant effects in major depression. Intranasal esketamine has recently come onto the market as an antidepressant. Besides experience from short-term use in anaesthesia and analgesia, the experience with ketamine as long-term medication is rather low. The use of ketamine and esketamine is limited due to potential neurotoxicity, psychotomimetic side effects, potential abuse and interindividual variability in treatment response including cessation of therapy. Therefore, taking a look at individual patient risks and potential underlying variability in pharmacokinetics may improve safety and dosing of these new antidepressant drugs in clinical practice. Differential drug metabolism due to polymorphic cytochrome P450 (CYP) enzymes and gene-drug interactions are known to influence the efficacy and safety of many drugs. Ketamine and esketamine are metabolized by polymorphic CYP enzymes including CYP2B6, CYP3A4, CYP2C9 and CYP2A6. In antidepressant drug therapy, usually multiple drugs are administered which are substrates of CYP enzymes, increasing the risk for drug-drug interactions. We reviewed the potential impact of polymorphic CYP variants and common drug-drug interactions in antidepressant drug therapy affecting ketamine pharmacokinetics, and the role for dose optimization. The use of ketamine or intranasal esketamine as antidepressants demands a better understanding of the factors that may impact its metabolism and efficacy in long-term use. In addition to other clinical and environmental confounders, prior information on the pharmacodynamic and pharmacokinetic determinants of response variability to ketamine and esketamine may inform on dose optimization and identification of individuals at risk of adverse drug reactions.
引用
- Langmia IM, Just KS, Yamoune S, et al. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective. Br J Clin Pharmacol. 2022. PMID: 35863300. doi:10.1111/bcp.15467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。